New approaches to modulating idiopathic pulmonary fibrosis.
New approaches to modulating idiopathic pulmonary fibrosis.
复制标题
DOI:
10.1007/s11882-013-0377-5
复制
发表时间:
2013-12
影响因子:
5.5
通讯作者:
Gomer, Richard H.
中科院分区:
文献类型:
--
作者:
Gomer, Richard H.
关键词:
Until recently, idiopathic pulmonary fibrosis (IPF) has been a devastating and generally fatal disease with no effective therapeutic. New developments in understanding the biology of the disease include a growing consensus that the lesions are mainly composed of cells that originated from resident fibroblasts. New developments in therapeutics include recommendations against several treatment regimes that have been previously used. On a positive note, the orally available drug pirfenidone has been approved for use in IPF in China, Japan, India, and the European Union, but not yet in the United States. Other possibilities for managing IPF include managing gastrointestinal reflux, and limiting excessive salt intake. A variety of potential therapeutics for IPF are in clinical trials; for instance in a Phase 1b trial, intravenous injections of a recombinant version of the normal human serum protein Serum Amyloid P (SAP, also known as PTX2) improved lung function in IPF patients.
登录
查看更多内容
影响因子:
3.7
作者:
Murray LA;Rosada R;Moreira AP;Joshi A;Kramer MS;Hesson DP;Argentieri RL;Mathai S;Gulati M;Herzog EL;Hogaboam CM
通讯作者:
Hogaboam CM
DOI:
10.1146/annurev-pathol-020712-163930
发表时间:
2013-01-24
期刊:
Annual review of pathology
影响因子:
--
作者:
Duffield JS;Lupher M;Thannickal VJ;Wynn TA
通讯作者:
Wynn TA
影响因子:
3.7
作者:
Jiang C;Hamm JP;Lim VK;Kirk IJ;Chen X;Yang Y
通讯作者:
Yang Y
DOI:
10.1164/rccm.200906-0964oc
发表时间:
2010-03-15
影响因子:
24.7
作者:
Daniels, Craig E.;Lasky, Joseph A.;Schroeder, Darrell R.
通讯作者:
Schroeder, Darrell R.
影响因子:
2.9
作者:
Naylor, Michelle C.;Lazar, David A.;Olutoye, Oluyinka O.
通讯作者:
Olutoye, Oluyinka O.